About ACRX

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. The company's late-stage pipeline includes ARX-04 (sufentanil sublingual tablet, 30 mcg) for the treatment of moderate-to-severe acute pain in a medically supervised setting; and Zalviso (sufentanil sublingual tablet system) for the management of moderate-to-severe acute pain in adult patients in the hospital setting.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ACRX is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 226.4 M 2.26416E+08 237 237 0.01% 0.000135137 64 K 64125
UBIO Proshares UltraPro Nasdaq Biotechnology 28.3 M 2.83481E+07 228 228 0.01% 8.89493E-05 8 K 7859
IBB iShares Nasdaq Biotechnology Index Fund 7.4 B 7.3951E+09 222 222 0.03% 0.0003 2.3 M 2272150
ITOT iShares Core S&P Total U.S. Stock Market ETF 19.7 B 1.97445E+10 3,547 3547 0.0% 0 199 K 198743
IWC iShares Microcap ETF 867.6 M 8.67563E+08 1,434 1434 0.05% 0.0005 414 K 414419
VTI Vanguard Total Stock Market ETF 109.6 B 1.096E+11 3,588 3588 0.0% 1E-05 895 K 894880
VXF Vanguard Extended Market ETF 6.7 B 6.7E+09 3,245 3245 0.01% 5E-05 328 K 328170